101 LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 IN STEMI VS NSTE-ACS PATIENTS: A MARKER OF CARDIOVASCULAR ATHEROSCLEROTIC RISK RATHER THAN THROMBOSIS

Abstract Background The precise role of Lipoprotein associated phospholipase A2 (Lp-PlA2) in the pathogenesis acute coronary syndromes (ACS) and prediction future cardiovascular events is still debated. So far, few data exist on variations Lp-PlA2 activity ACS especially NSTE-ACS vs STEMI patients, where thrombotic atherosclerotic mechanisms could play a differential role. aim present study was, then, to compare according type presentation. Methods A consecutive cohort patients undergoing angiography for syndrome were included divided presentation non ST-segment elevation-ACS or elevation Myocardial Infarction (STEMI). Lp-PLA2 was assessed blood samples drawn at admission using Diazyme Activity Assay. Results We our 117 whom 31 (26.5%) presented with STEMI. significantly younger (p=0.05), displayed lower rate hypertension (p=0.002), previous MI (p=0.001) PCI (p=0.01) used less frequently statins clopidogrel (p=0.02). White cells glycemia increased (p=0.001, respectively). prevalence severity CAD not different types, but higher thrombus (p<0.001) TIMI flow (p=0.002) levels as compared (132±41.1 154.6 ±40.9 nmol/min/mL, p=0.01). In fact, above median (148 nmol/min/mL) (32.3% 57%, p=0.02, adjusted OR[95% CI]=0.20[0.06-0.68], p=0.010). Moreover, direct linear relationship observed between LDL-C (r=0.47, p<0.001), inflammatory biomarkers. Conclusion shows that among are inversely occlusion, being instead recurrent events, therefore potentially representing marker more aggressive disease burden risk.